대장암에서의 항암제 감수성 검사의 임상적 특성에 관한 초기 연구
Preliminary Study of the Clinical Features of the Chemosensitivity Test in Colorectal Cancer
박찬섭, 최성호, 김홍대,
소속 상세정보
박찬섭 ( Park Chan-Sup )
성균관대학교 의과대학 강북삼성병원 외과학교실
최성호 ( Choi Seong-Ho )
성균관대학교 의과대학 삼성서울병원 외과
김홍대 ( Kim Hung-Dae )
이수앱지스
KMID : 0356720070230050358
Abstract
Purpose: Colorectal cancers have been known to be refractory to chemotherapy in the past decades. Recently, novel agents have been developed and various data have shown an improved response rate and a survival benefit. However, considerable heterogeneity exists between cancers of the same tissue type, including colorectal cancer. Thus, Individualized chemotherapy that is tailored specifically to the characteristics of the tumor is necessary for an improved clinical outcome.
Methods: We evaluate the chemosensitivity of colorectal cancer to standard drugs (5-FU, oxaliplatin, and irinotecan) and to drugs used for other cancers (mitomycin, paclitaxel, and gemcitabine) by using Adenosine-triphosphate-based chemotherapy response assay (ATP-CRA).
Results: The degree of in-vitro response to a single anticancer medication was highest for 5-FU. According to stages, 5-FU is the most sensitive chemotherapeutic agent in Duke’s B, irinotecan in Duke’s C, and 5-FU in Duke’s D patients. With tumor location, irinotecan is most sensitive in colon cancers and 5-FU in rectal cancers. The effect of treatment is superior in the test- guided therapy group in Duke’s D colorectal cancer patients.
Conclusions: Chemosensitivity tests may be useful in selecting optimum drugs for patient who require chemotherapy. However, the results of this study do not strongly support the usefulness of this assay; further studies with a sufficient number of cases and an extended observation period are ongoing
키워드
항암제 감수성 검사;대장암
Adenosine-triphosphate-based chemotherapy response assay (ATP-CRA);Colorectal cancer
원문 및 링크아웃 정보
등재저널 정보